Individual Response to Radiation of Individuals with Neurofibromatosis Type I: Role of the ATM Protein and Influence of Statins and Bisphosphonates
P. Combemale(Centre Léon Bérard), Nicolas Foray(Inserm), Mona Amini‐Adlé(Centre Léon Bérard), Larry Bodgi(Inserm), Michel Bourguignon(Centre Hospitalier d'Orsay), Joëlle Al-Choboq(Inserm), Steven Franck Burlet(Inserm), Clément Devic(Inserm), Mélanie L. Ferlazzo(Inserm), Jacques Balosso, Adeline Granzotto(Inserm), Jean-Thomas Bachelet(Inserm), S. Pinson(Hôpital Edouard Herriot), Laurène Sonzogni(Inserm), Zuzana Bencokova(Churchill Hospital)
Cited by 27
Related Papers
Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial
|The Lancet Oncology|2015|432
Effects of Acute versus Chronic Hypoxia on DNA Damage Responses and Genomic Instability
|Cancer Research|2010|205
Long‐term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42‐month analysis of the phase II randomized, double‐blind BOLT study
|British Journal of Dermatology|2019|197
Translocation, t(17;22)(q22;q13), in dermatofibrosarcoma protuberans: a new tumor-associated chromosome rearrangement
|Cytogenetics and Cell Genetics|2008|194
Long‐term efficacy and safety of sonidegib in patients with locally advanced and metastatic basal cell carcinoma: 30‐month analysis of the randomized phase 2 BOLT study
|Journal of the European Academy of Dermatology and Venereology|2017|192